Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial.

Cristina Marcelo-Calvo, Andrés Esteban-Cantos, Francisco Jurado, Rocío Montejano, Javier Rodríguez-Centeno, Lucía Gutiérrez-García, Alejandro de Gea-Grela, Patricia Martínez-Martín, Alejandro Díez Vidal, Rosa de Miguel, Carlos M Oñoro-López, Juan Carlos González, Luz Martín-Carbonero, José Ignacio Bernardino, Rocío Menéndez Colino, Noemí González Pérez de Villar, Berta Rodés, José Ramón Arribas

Department of Internal Medicine, HIV Unit, La Paz University Hospital, Madrid, Spain.Department of Internal Medicine, HIV Unit, La Paz University Hospital, Madrid, Spain. · pubmed

Paper

Abstract

Metformin is increasingly studied as a potential geroprotective agent in the general population. We aimed to test the efficacy and safety of metformin to improve epigenetic age in older, well-controlled, non-diabetic people living with HIV.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that metformin can improve epigenetic age in older, non-diabetic individuals living with HIV. This study is relevant as it explores a potential intervention (metformin) that may address underlying mechanisms of aging rather than merely treating age-related symptoms.

Author of this paper? Send a correction.